Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

immuno-PET

  • Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma
    You have access
    Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma
    Zhen Yang, Feng Li, Yuqian Huang, Na Yin, Junjun Chu, Ying Ma, Roderic I. Pettigrew, Dale J. Hamilton, Diego R. Martin and Zheng Li
    Journal of Nuclear Medicine November 1, 2022, 63 (11) 1708-1714; DOI: https://doi.org/10.2967/jnumed.121.263151
  • <sup>89</sup>Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
    You have access
    89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
    Sarah R. Verhoeff, Pim P. van de Donk, Erik H.J.G. Aarntzen, Sjoukje F. Oosting, Adrienne H. Brouwers, Iris H.C. Miedema, Jens Voortman, Willemien C. Menke-van der Houven van Oordt, Ronald Boellaard, Dennis Vriens, Marije Slingerland, Rick Hermsen, Ilse van Engen-van Grunsven, Sandra Heskamp and Carla M.L. van Herpen
    Journal of Nuclear Medicine October 1, 2022, 63 (10) 1523-1530; DOI: https://doi.org/10.2967/jnumed.121.263470
  • You have access
    Single-Domain Antibody Theranostics on the Horizon
    Weijun Wei, Muhsin H. Younis, Xiaoli Lan, Jianjun Liu and Weibo Cai
    Journal of Nuclear Medicine October 1, 2022, 63 (10) 1475-1479; DOI: https://doi.org/10.2967/jnumed.122.263907
  • Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3
    You have access
    Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3
    Joshua A. Korsen, Teja M. Kalidindi, Samantha Khitrov, Zachary V. Samuels, Goutam Chakraborty, Julia A. Gutierrez, John T. Poirier, Charles M. Rudin, Yu Chen, Michael J. Morris, Nagavarakishore Pillarsetty and Jason S. Lewis
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1401-1407; DOI: https://doi.org/10.2967/jnumed.121.263221
  • Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM
    You have access
    Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM
    Sai Kiran Sharma, Maya Suzuki, Hong Xu, Joshua A. Korsen, Zachary Samuels, Hongfen Guo, Brandon Nemieboka, Alessandra Piersigilli, Kimberly J. Edwards, Nai-Kong V. Cheung and Jason S. Lewis
    Journal of Nuclear Medicine April 1, 2022, 63 (4) 629-636; DOI: https://doi.org/10.2967/jnumed.121.262383
  • Site-Specific and Residualizing Linker for <sup>18</sup>F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment
    You have access
    Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment
    Zhengyuan Zhou, Rebecca Meshaw, Michael R. Zalutsky and Ganesan Vaidyanathan
    Journal of Nuclear Medicine November 1, 2021, 62 (11) 1624-1630; DOI: https://doi.org/10.2967/jnumed.120.261446
  • Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
    You have access
    Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer
    Kelly E. Henry, Travis M. Shaffer, Kyeara N. Mack, Janine Ring, Anuja Ogirala, Susanne Klein-Scory, Christina Eilert-Micus, Wolff Schmiegel, Thilo Bracht, Barbara Sitek, Marguerite Clyne, Colm J. Reid, Bence Sipos, Jason S. Lewis, Holger Kalthoff and Jan Grimm
    Journal of Nuclear Medicine October 1, 2021, 62 (10) 1384-1390; DOI: https://doi.org/10.2967/jnumed.120.256776
  • Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
    You have access
    Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
    Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, Frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, Delphine Drui, David M. Goldenberg, Robert M. Sharkey, Jacques Barbet and Francoise Kraeber-Bodere
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1221-1227; DOI: https://doi.org/10.2967/jnumed.120.252791
  • 
<sup>89</sup>Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    You have access
    89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
    Kyung-Ho Jung, Jin Won Park, Jin Hee Lee, Seung Hwan Moon, Young Seok Cho and Kyung-Han Lee
    Journal of Nuclear Medicine May 10, 2021, 62 (5) 656-664; DOI: https://doi.org/10.2967/jnumed.120.250720
  • Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
    Open Access
    Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
    Patricia M.R. Pereira, Jalen Norfleet, Jason S. Lewis and Freddy E. Escorcia
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 366-371; DOI: https://doi.org/10.2967/jnumed.120.244897

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire